QUOTE AND NEWS
MedPage Today  Jun 28  Comment 
(MedPage Today) -- A futility analysis finds pioglitazone won't help slow disease progression
Financial Times  Jun 24  Comment 
Nestlé poaches executive from pharma group in throes of international push
FiercePharma  Jun 5  Comment 
Orexigen and Takeda have already had their fair share of headaches over obesity med Contrave this year after a data leak forced the pair to abandon a postmarketing heart study. Now, though, they've got a generic to fend off, and they've sued maker...
FierceBiotech  Jun 2  Comment 
The unending game of global reorganization in biopharma R&D is continuing with a new move by Takeda to shutter several vaccines operations scattered around the U.S. with plans to concentrate its efforts and the work now done by about 150 staffers...
GenEng News  May 28  Comment 
Sanford-Burnham Medical Research Institute at Lake Nona said today it is launching a two-year partnership with Takeda Pharmaceutical focused on treating heart failure. The value of the collaboration was not disclosed. The partners will study...
Japan Today  May 15  Comment 
Japan's top drugmaker on Friday reported an annual loss for the first time in its history after agreeing to pay $2.4 billion to settle U.S. lawsuits over cancer claims regarding its Actos diabetes drug. Osaka-based Takeda Pharmaceutical said...
FiercePharma  May 15  Comment 
In his debut earnings report since assuming his role as CEO of Japanese drugmaker Takeda, Christophe Weber had to tell investors today that the company had a small loss in its last fiscal year.
FiercePharma  May 14  Comment 
Turns out the FDA isn't the only one that's been ticked off with Orexigen since it released some early positive cardio data for obesity drug, Contrave, last March. Marketing partner Takeda is on that list, too--and earlier this week, the Japanese...
FiercePharma  May 13  Comment 
The FDA was none too happy with Orexigen when it put out some early positive cardio data for obesity drug Contrave in March. One reason? Early data can be misleading--and now, it looks like that might have been the case for Contrave.




 
TOP CONTRIBUTORS

No more s***. All posts of this qaultiy from now on

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki